Venus MedTech FY25 net loss narrows 43.2% to RMB 410 million; revenue falls 34.8% to RMB 310 million

Reuters04-01

Venus MedTech FY25 net loss narrows 43.2% to RMB 410 million; revenue falls 34.8% to RMB 310 million

Venus Medtech posted a net loss attributable to owners of RMB 408 million, narrowing 42.9%, with loss per share at RMB 0.93.
Revenue fell 34.8% to RMB 307 million, due to lower unit prices and sales volumes amid fiercer competition in China.
Adjusted non-IFRS EBITDA was RMB 250 million, little changed with a 1.3% improvement.
Overseas revenue rose 19.2% to RMB 98.3 million, while cash and cash equivalents declined 46.9% to RMB 158 million.
Pipeline updates included full enrollment of 150 patients for Cardiovalve’s EU pivotal trial with CE MDR submission, while VenusP-Valve’s U.S. IDE pivotal study stayed on track.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260331-12084699), on March 31, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624155537?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 05:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624155537","market":"fut","top_or_hot":-1,"title":"Venus MedTech FY25 net loss narrows 43.2% to RMB 410 million; revenue falls 34.8% to RMB 310 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Venus MedTech FY25 net loss narrows 43.2% to RMB 410 million; revenue falls 34.8% to RMB 310 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Venus Medtech posted a net loss attributable to owners of RMB 408 million, narrowing 42.9%, with loss per share at RMB 0.93.\n        </li>\n<li>\n          Revenue fell 34.8% to RMB 307 million, due to lower unit prices and sales volumes amid fiercer competition in China.\n        </li>\n<li>\n          Adjusted non-IFRS EBITDA was RMB 250 million, little changed with a 1.3% improvement.\n        </li>\n<li>\n          Overseas revenue rose 19.2% to RMB 98.3 million, while cash and cash equivalents declined 46.9% to RMB 158 million.\n        </li>\n<li>\n          Pipeline updates included full enrollment of 150 patients for Cardiovalve’s EU pivotal trial with CE MDR submission, while VenusP-Valve’s U.S. IDE pivotal study stayed on track.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260331-12084699), on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Venus MedTech FY25 net loss narrows 43.2% to RMB 410 million; revenue falls 34.8% to RMB 310 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVenus MedTech FY25 net loss narrows 43.2% to RMB 410 million; revenue falls 34.8% to RMB 310 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-01 05:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Venus MedTech FY25 net loss narrows 43.2% to RMB 410 million; revenue falls 34.8% to RMB 310 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Venus Medtech posted a net loss attributable to owners of RMB 408 million, narrowing 42.9%, with loss per share at RMB 0.93.\n        </li>\n<li>\n          Revenue fell 34.8% to RMB 307 million, due to lower unit prices and sales volumes amid fiercer competition in China.\n        </li>\n<li>\n          Adjusted non-IFRS EBITDA was RMB 250 million, little changed with a 1.3% improvement.\n        </li>\n<li>\n          Overseas revenue rose 19.2% to RMB 98.3 million, while cash and cash equivalents declined 46.9% to RMB 158 million.\n        </li>\n<li>\n          Pipeline updates included full enrollment of 150 patients for Cardiovalve’s EU pivotal trial with CE MDR submission, while VenusP-Valve’s U.S. IDE pivotal study stayed on track.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260331-12084699), on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL13PGY6:1","article_id":"2624155537","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624155537","pubTimestamp":1774992662,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Venus Medtech posted a net loss attributable to owners of RMB 408 million, narrowing 42.9%, with loss per share at RMB 0.93.Revenue fell 34.8% to RMB 307 million, due to lower unit prices and sales volumes amid fiercer competition in China.Adjusted non-IFRS EBITDA was RMB 250 million, little changed with a 1.3% improvement.Overseas revenue rose 19.2% to RMB 98.3 million, while cash and cash equivalents declined 46.9% to RMB 158 million.Pipeline updates included full enrollment of 150 patients for Cardiovalve’s EU pivotal trial with CE MDR submission, while VenusP-Valve’s U.S. IDE pivotal study stayed on track.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","BK1574":"生物医药B类股","02500":"启明医疗-B","BK1583":"高瓴概念"},"translate_title":"启明医疗25财年净亏损收窄43.2%至人民币4.1亿元；收入下降34.8%至人民币3.1亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02500":0.9},"content_text":"Venus MedTech FY25 net loss narrows 43.2% to RMB 410 million; revenue falls 34.8% to RMB 310 million\n    \n\n\n          Venus Medtech posted a net loss attributable to owners of RMB 408 million, narrowing 42.9%, with loss per share at RMB 0.93.\n        \n\n          Revenue fell 34.8% to RMB 307 million, due to lower unit prices and sales volumes amid fiercer competition in China.\n        \n\n          Adjusted non-IFRS EBITDA was RMB 250 million, little changed with a 1.3% improvement.\n        \n\n          Overseas revenue rose 19.2% to RMB 98.3 million, while cash and cash equivalents declined 46.9% to RMB 158 million.\n        \n\n          Pipeline updates included full enrollment of 150 patients for Cardiovalve’s EU pivotal trial with CE MDR submission, while VenusP-Valve’s U.S. IDE pivotal study stayed on track.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260331-12084699), on March 31, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624155537","isCrawlerRequest":true}